Minireviews
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Nov 27, 2023; 15(11): 2398-2405
Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2398
Table 1 Treatment of post-cholecystectomy bile acid diarrhoea
Treatment
Target
Limited
Bile acid sequestrant trialBile acids secreted into the intestine are bound to reduce damage to intestinal tissuesPoorly tolerated due to stomach pain, bloating, flatulence, nausea and vomiting
Bile acid receptor agonistsReceptor agonists reduce bile acid synthesis to relieve symptoms of diarrhoeaPotent FXR agonists may have adverse side effects
Glucagon-like peptide 1 receptor agonistSlows upper gastrointestinal motility and increases small intestine transit timeFurther clinical trials and follow-up required
Intestinal microbiotaIncreased bile acid binding, excretion in faeces, and hepatic synthesis via an FGF-dependent mechanism after probiotic administrationNot intended to target the entire intestinal microbial community as a therapeutic approach
Ursodeoxycholic acidReduces mucosal cytokine levels, inhibiting release of antimicrobial peptides and preventing apoptosis.LCA metabolism may be required to allow full pharmacological effects of ursodeoxycholic acid
Anti-diarrhoeal agentsInhibit intestinal secretion and peristalsis, slowing intestinal transit and allowing increased fluid reabsorption to alleviate diarrheal symptomsHigh doses or abuse may cause cardiotoxicity
Dietary therapyVegetable dietary fiber prevents gastrointestinal diarrhea by reducing gastric emptyingMay respond to a reduction of dietary cholesterol and fats